Taysha Gene Therapies (TSHA) Earnings Date & Reports

Key Takeaways

• Taysha Gene Therapies is expected to report third-quarter 2026 results in early-to-mid November 2026, marking its next scheduled quarterly earnings update.
• Wall Street consensus points to a net loss of roughly $0.12 to $0.14 per share, with minimal revenue expected for the period.
• As a clinical-stage biotechnology company, Taysha's reported results matter less than updates on its lead candidate, TSHA-102 for Rett syndrome.
• Investors will focus on research and development (R&D) spending, cash runway, and any new clinical or regulatory milestones.
• Taysha reported a net loss of $0.13 per share in the second quarter of 2026, and its shares have shown notable post-earnings volatility over the past year.
• For more detail on Taysha Gene Therapies, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Discover new trading ideas with Trending AI Robots.

Earnings Context and Why It Matters

Taysha Gene Therapies (TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe central nervous system (CNS) diseases, led by TSHA-102 for Rett syndrome. Because the company generates little recurring revenue, its quarterly earnings are primarily a window into how efficiently it is funding clinical development. R&D expenses have climbed sharply as the pivotal REVEAL trial for TSHA-102 advances, making cash management a central theme for investors. With the stock trading well below its 52-week high and showing elevated short interest, the upcoming report will be closely watched for signals on trial timelines, spending discipline, and how far the company's cash reserves can support operations.

Earnings Expectations

Consensus estimates call for Taysha to report a net loss of approximately $0.12 to $0.14 per share for the third quarter of 2026, with revenue expected to remain minimal—roughly $0.6 million to $0.8 million. For context, the company reported a net loss of $0.13 per share in the second quarter of 2026, with essentially no product revenue, as its clinical programs have not yet reached commercialization.

Rather than revenue or bottom-line figures, the metrics that matter most are R&D expense, net cash used in operations, and the reported cash balance. Taysha has emphasized that its cash position is expected to fund operations into 2028, so investors will scrutinize whether spending remains on track with that guidance. Updates on TSHA-102 dosing, patient enrollment, and any safety readouts will likely carry more weight than the headline loss itself.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors tracking names like TSHA or scanning the broader biotechnology space, it offers a structured way to surface actionable candidates.

Market Reaction and Investor Sentiment

Heading into the third-quarter report, sentiment around TSHA remains cautious but attentive to pipeline catalysts. The stock has experienced substantial post-earnings swings over the past year, with past releases generating outsized moves as investors react to clinical updates rather than financial line items. Elevated short interest also suggests a segment of the market is positioning against the shares, which can amplify volatility around the print. The key risk is an unchanged or worsening spending trajectory without a corresponding clinical catalyst, while the primary upside signal would be a clearer, on-time path for TSHA-102 through its pivotal trial.

Forward Outlook and Key Factors to Monitor

Following the report, investors should focus on guidance surrounding the company's cash runway and the pace of R&D spending. Taysha has previously indicated its cash is expected to fund operations into 2028, so any adjustment to that outlook would be a meaningful signal.

Clinical milestones for TSHA-102 in Rett syndrome remain the most important forward-looking catalysts. Updates on patient dosing, enrollment progress in the pivotal REVEAL trial, and any emerging safety or efficacy data will likely drive the stock more than the quarterly loss figure.

Broader industry conditions also matter. Biotechnology funding and sentiment can shift with interest-rate expectations and investor appetite for risk, influencing how the market values a pre-revenue, clinical-stage company. Cost discipline, manufacturing readiness for gene therapy, and regulatory feedback will be additional factors to watch in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations